Smith & Nephew SNATS

Smith & Nephew SNATS EBITDA per Employee

The EBITDA per Employee of Smith & Nephew SNATS (SNN) as of Nov 4, 2026 is 45,293.78 USD. In the previous year, EBITDA per Employee was 37,478.61 USD — a change of 20.85% (higher).

EBITDA per Employee

45,293.78USD

YoY

20.85%

Last updated:

EBITDA per Employee of Smith & Nephew SNATS is 2025 45,293.78 USD. EBITDA per Employee of Smith & Nephew SNATS was 2024 37,478.61 USD. It decreases by 20.85% higher compared to the previous year.

The Smith & Nephew SNATS EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2018
49,229.89 USD
Jan 1, 2019
46,491.73 USD
Jan 1, 2020
16,828.29 USD
Jan 1, 2021
33,827.72 USD
Jan 1, 2022
25,670.28 USD
Jan 1, 2023
24,244.15 USD
Jan 1, 2024
37,478.61 USD
Jan 1, 2025
45,293.78 USD
The Smith & Nephew SNATS EBITDA per Employee history
YEAREBITDA per EmployeeYoY
45,293.78USD+20.85%
37,478.61USD+54.59%
24,244.15USD-5.56%
25,670.28USD-24.11%
33,827.72USD+101.02%
16,828.29USD-63.80%
46,491.73USD-5.56%
49,229.89USD-7.60%
53,280.09USD+16.60%
45,693.10USD+27.55%
35,824.30USD-16.15%
42,726.75USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Smith & Nephew SNATS Stock analysis

What does Smith & Nephew SNATS do? Smith & Nephew SNATS Inc operates in the medical device sector, focusing on orthopaedic implants and surgical solutions. The company generates revenue through knee and hip implant products used in joint replacement procedures, including revision surgeries. Its trauma and extremities segment offers internal and external devices for fracture stabilization and deformity correction. Sports Medicine & ENT segment sells joint repair products, arthroscopic equipment, and tissue resection devices for minimally invasive surgeries. Advanced Wound Management provides specialized wound care solutions, though specific products are not detailed in the description. The primary buyers are healthcare providers and hospitals globally, particularly in the United Kingdom, United States, and international markets. Orthopaedics and Sports Medicine & ENT segments target surgeons and orthopaedic specialists, while Advanced Wound Management serves wound care professionals. The company’s products are sold under its own brand, with no external brand names mentioned in the description. Revenue streams include direct sales of medical devices to hospitals and clinics, with no mention of subscription models or service-based fees. The company’s focus on surgical solutions and implants drives its market position, with key segments defined by product categories rather than geographic regions. No additional revenue streams like data services or digital platforms are referenced in the business description. Smith & Nephew SNATS is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Smith & Nephew SNATS stock

EBITDA per Employee of Smith & Nephew SNATS is 45,293.78 USD in 2025.

EBITDA per Employee of Smith & Nephew SNATS changed from 37,478.61 USD to 45,293.78 USD, representing a 20.85% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Smith & Nephew SNATS since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Smith & Nephew SNATS historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Smith & Nephew SNATS

All Key Metrics — Smith & Nephew SNATS